References
- Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006;36(11):792–1540.
- Desai PR, Lawson KA, Barner JC, et al. Estimating the direct and indirect costs for community-dwelling patients with schizophrenia. J Pharm Health Serv Res. 2013;4(4):187–194.
- National Alliance on Mental Illness. Mental health by the number Arlington, VA2021. [cited 2021 Sep 28]. Available from: https://www.nami.org/mhstats.
- Pilon D, Patel C, Lafeuille MH, et al. Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries. Curr Med Res Opin. 2021;37(10):1811–1819.
- Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62.
- Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.
- Beadles CA, Ellis AR, Lichstein JC, et al. First outpatient follow-up after psychiatric hospitalization: does one size fit all? Psychiatr Serv. 2015;66(4):364–372. Apr 1
- Marcus SC, Chuang CC, Ng-Mak DS, et al. Outpatient follow-up care and risk of hospital readmission in schizophrenia and bipolar disorder. Psychiatr Serv. 2017;68(12):1239–1246. Dec 1
- Centers for Medicare and Medicaid Services. Quality measures. 2020. [cited 2021 Oct 20]. Available from: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures.
- Centers for Medicare and Medicaid Services. Core set of behavioral health measures for Medicaid and CHIP (behavioral health core set). 2021. [cited 2021 Oct 28]. Available from: https://www.medicaid.gov/medicaid/quality-of-care/downloads/2021-bh-core-set.pdf.
- Patel C, Emond B, Morrison L, et al. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study. Curr Med Res Opin. 2021;37(4):665–674.
- Waters HC, Ruetsch C, Tkacz J. A claims-based algorithm to reduce relapse and cost in schizophrenia. Am J Manag Care. 2019;25(12):e373–e378.
- Pompili M, Giordano G, Luciano M, et al. Unmet needs in schizophrenia. CNS Neurol Disord Drug Targets. 2017;16(8):870–884.
- Pilon D, Tandon N, Lafeuille MH, et al. Treatment patterns, health care resource utilization, and spending in Medicaid beneficiaries initiating second-generation long-acting injectable agents versus oral atypical antipsychotics. Clin Ther. 2017;39(10):1972–1985.e2.
- Pilon D, Patel C, Zuckerman P, et al. Antipsychotic treatment utilization and healthcare spending in medicaid beneficiaries by state and region within the United States Psych Congress 2020; September 10–13, 2020. Virtual 2020.
- El Khoury AC, Pilon D, Morrison L, et al. Projecting the long-term economic impact of once-monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. J Manag Care Spec Pharm. 2020;26(2):176–185.
- Lin D, Thompson-Leduc P, Ghelerter I, et al. Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis. CNS Drugs. 2021;35(5):469–481.
- Patel C, Emond B, Lafeuille MH, et al. Real-world analysis of switching patients with schizophrenia from oral risperidone or oral paliperidone to once-monthly paliperidone palmitate. Drugs Real World Outcomes. 2020;7(1):19–29.
- Zhdanava M, Lin D, Lafeuille MH, et al. Antipsychotic adherence, resource use, and costs before and after the initiation of once-monthly paliperidone palmitate therapy among Medicaid beneficiaries with prior schizophrenia relapse. Clin Ther. 2021;43(3):535–548.
- American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Washington (DC): APA; 2021. p. 1–312.
- Mental Health Clinical Advisory Group. Mental health care guide for licensed practitioners and mental health professionals. Salem (OR): Oregon Health Authority; 2019.
- Florida Medicaid Drug Therapy Management Program for Behavioral Health. 2019-2020 Florida best practice psychotherapeutic medication guidelines for adults. 2020. p. 1–78. Available from: https://floridabhcenter.org/wp-content/uploads/2021/04/2019-Psychotherapeutic-Medication-Guidelines-for-Adults-with-References_06-04-20.pdf.
- Citrome L. Long-acting injectable antipsychotics: what, when, and how. CNS Spectr. 2021;26(2):118–129.
- Center for Medicare Advocacy. Medicare coverage for people with disabilities. 2022. [cited 2022 Apr 8]. Available from: https://medicareadvocacy.org/medicare-info/medicare-coverage-for-people-with-disabilities/#is%20available.
- US Department of Health and Human Services. 45 CFR 46: pre-2018 requirements. 2021. [cited 2021 Nov 10]. Available from: https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html#46.101.
- Centers for Medicare and Medicaid Services. Inpatient psychiatric facility quality reporting program manual. 2021. [cited 2022 Jan 6]. Available from: https://qualitynet.cms.gov/ipf/ipfqr.
- Centers for Medicare and Medicaid Services. Hospital quality initiative: measure methodology. 2021. [cited 2022 Jan 6]. Available from: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.
- Medicare.gov. Medicaid. 2022. [cited 2022 Mar 9]. Available from: https://www.medicare.gov/your-medicare-costs/get-help-paying-costs/medicaid.
- Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387–404.
- Marcus SC, Zummo J, Pettit AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm. 2015;21(9):754–769.
- Agency for Healthcare Research and Quality. Hospital readmissions involving psychiatric disorders, 2012. 2015. [cited 2021 Nov 3]. Available from: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb189-Hospital-Readmissions-Psychiatric-Disorders-2012.jsp.
- Agency for Healthcare Research and Quality. Characteristics of hospital stays for super-utilizers by payer, 2012. 2015. [cited 2022 May 16]. Available from: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb190-Hospital-Stays-Super-Utilizers-Payer-2012.jsp.
- Douthit N, Kiv S, Dwolatzky T, et al. Exposing some important barriers to health care access in the rural USA. Public Health. 2015;129(6):611–620.
- National Council for Mental Wellbeing. CCBHC locator. 2021. [cited 2021 Aug 16]. Available from: https://www.thenationalcouncil.org/ccbhc-success-center/ccbhc-locator/.
- National Alliance of State Pharmacy Association. Pharmacist authority to administer long-acting antipsychotic. 2019. [cited 2021 Aug 11]. Available from: https://naspa.us/wp-content/uploads/2017/07/Pharmacists-Authority-to-Administer-Medications.pdf.
- Kaiser Family Foundation. Status of state Medicaid expansion decisions. 2021. [cited 2021 Aug 11]. Available from: https://www.kff.org/medicaid/issue-brief/status-of-state-medicaid-expansion-decisions-interactive-map/.